<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263055</url>
  </required_header>
  <id_info>
    <org_study_id>R_9262</org_study_id>
    <nct_id>NCT00263055</nct_id>
  </id_info>
  <brief_title>MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV</brief_title>
  <official_title>Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Safety &amp; tolerability of FOLFOX4 regimen in the adjuvant treatment of colon cancer in Asian
      patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicity</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of one or more adverse event in a patient</measure>
    <time_frame>From the Informed Consent Form (ICF) signature to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall distribution of intensity of adverse events</measure>
    <time_frame>from the inform consnet signed up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of particular adverse events and their intensities</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients completing study treatment</measure>
    <time_frame>from the inform consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with grade 1, 2 and 3 neuropathy</measure>
    <time_frame>at 28 days, 6 months and 12 months after last chemotherapy administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of intended dose delivered for 5-FU/LV and Oxaliplatin</measure>
    <time_frame>from the informed consent signed up to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delays in scheduled dosing</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity, as expressed as the amount of 5-FU/LV and Oxaliplatin administered divided by the duration of treatment</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>•Survival Analysis •Laboratory assay and vital signs ECOG and KPS</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term toxicity</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <condition>Colonic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven stage Dukes &quot; B2 &quot; (stage II: T3-T4 N0 M0) and &quot; C &quot; (stage III:
             any T N1-2 M0) colon carcinoma. The inferior pole of the tumor must be above the
             peritoneal reflection (&gt; 15 cm from the anal margin).

          -  Patients must have undergone complete resection of the primary tumor without gross or
             microscopic evidence of residual disease

          -  Patients must be entered in the study in order to start treatment within 7 weeks after
             surgery

          -  Age 18-75 years old

          -  Performance Status ≤ 2 (Karnofsky &gt; or = 60%)

          -  No previous chemotherapy, immunotherapy or radiotherapy

          -  No biological major abnormalities :Absolute neutrophil count &gt; 1.5 x 10^9/l,Platelets
             ≥ 100 x 10^9/l,Serum creatinine ≤ 1.25 times the upper limit of normal, total
             bilirubin, ASAT / ALAT &lt; 2 times the upper limit of the normal range,carcinoembryonic
             antigen &lt; 10 ng/ml.

          -  Documentation of a negative pregnancy test must be available for premenopausal women
             with intact reproductive organs

          -  Men and women who are fertile must use a medically acceptable contraceptive throughout
             the treatment period and for 3 months following cessation of treatment with
             oxaliplatin. Subjects must be made aware, before entering this trial of the risk of
             becoming pregnant or in fathering children

          -  Signed informed consent obtained prior to study entry

        Exclusion criteria

          -  Pregnant or lactating women

          -  Women of child bearing potential not using a contraceptive method

          -  Previous cancer of the colon or rectum

          -  Previous malignancies other than adequately treated in situ carcinoma of the uterine
             cervix or basal or squamous cell carcinoma of the skin, unless there has been a
             disease-free interval of at least 10 years

          -  Participation in another clinical trial with any investigational drug within 30 days
             prior to randomization

          -  Peripheral neuropathy (NCI CTC [National Cancer Institute Common Toxicity Criteria] &gt;
             or = Grade I)

          -  Uncontrolled congestive heart failure or angina pectoris, or hypertension or
             arrhythmia

          -  History of significant neurologic or psychiatric disorders

          -  Active infection

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Valterio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

